AN2 Therapeutics, Inc. (ANTX)
NASDAQ: ANTX · Real-Time Price · USD
4.940
-0.500 (-9.19%)
At close: Mar 13, 2026, 4:00 PM EDT
4.910
-0.030 (-0.61%)
After-hours: Mar 13, 2026, 4:41 PM EDT
AN2 Therapeutics Employees
AN2 Therapeutics had 22 employees as of December 31, 2024. The number of employees decreased by 19 or -46.34% compared to the previous year.
Employees
22
Change (1Y)
-19
Growth (1Y)
-46.34%
Revenue / Employee
n/a
Profits / Employee
-$1,544,818
Market Cap
135.37M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 22 | -19 | -46.34% | 22 | 0 |
| Dec 31, 2023 | 41 | 5 | 13.89% | 41 | 0 |
| Mar 31, 2023 | 36 | 14 | 63.64% | 35 | 1 |
| Dec 31, 2022 | 36 | 14 | 63.64% | 35 | 1 |
| Sep 30, 2022 | 27 | 5 | 22.73% | 26 | 1 |
| Jun 30, 2022 | 25 | - | - | 25 | 0 |
| Mar 31, 2022 | 22 | - | - | 22 | 0 |
| Dec 31, 2021 | 22 | - | - | 22 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Karyopharm Therapeutics | 228 |
| Codexis | 188 |
| Sangamo Therapeutics | 183 |
| Innate Pharma | 174 |
| Rani Therapeutics Holdings | 106 |
| Nkarta | 105 |
| Precision BioSciences | 67 |
| Connect Biopharma Holdings | 62 |
ANTX News
- 2 days ago - AN2 Therapeutics Stock Cools Off After 90% Rally - Benzinga
- 4 days ago - AN2 Therapeutics Stock Jumps 90% Monday: What's Driving The Action? - Benzinga
- 4 days ago - AN2 Therapeutics Announces $40 Million Private Placement Financing - Business Wire
- 10 days ago - AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV) - Business Wire
- 24 days ago - AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference - Business Wire
- 2 months ago - AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M. abscessus Lung Disease - Business Wire
- 4 months ago - AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights - Business Wire
- 4 months ago - AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB) - Business Wire